177 related articles for article (PubMed ID: 30623492)
1. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia.
Levchenko A; Vyalova N; Pozhidaev IV; Boiko AS; Osmanova DZ; Fedorenko OY; Semke AV; Bokhan NA; Wilffert B; Loonen AJM; Ivanova SA
Hum Psychopharmacol; 2019 Jan; 34(1):e2685. PubMed ID: 30623492
[TBL] [Abstract][Full Text] [Related]
2. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia.
Zai CC; Romano-Silva MA; Hwang R; Zai GC; Deluca V; Müller DJ; King N; Voineskos AN; Meltzer HY; Lieberman JA; Potkin SG; Remington G; Kennedy JL
Schizophr Res; 2008 Dec; 106(2-3):248-52. PubMed ID: 18838251
[TBL] [Abstract][Full Text] [Related]
3. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.
Koning JP; Vehof J; Burger H; Wilffert B; Al Hadithy A; Alizadeh B; van Harten PN; Snieder H;
Psychopharmacology (Berl); 2012 Feb; 219(3):727-36. PubMed ID: 21750899
[TBL] [Abstract][Full Text] [Related]
4. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
5. Implications of Antipsychotic Use: Antipsychotic-Induced Movement Disorders, with a Focus on Tardive Dyskinesia.
Dilks S; Xavier RM; Kelly C; Johnson J
Nurs Clin North Am; 2019 Dec; 54(4):595-608. PubMed ID: 31703784
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
Lanning RK; Zai CC; Müller DJ
Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
[TBL] [Abstract][Full Text] [Related]
7. Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates.
Hernandez G; Mahmoudi S; Cyr M; Diaz J; Blanchet PJ; Lévesque D
Mov Disord; 2019 May; 34(5):717-726. PubMed ID: 30675935
[TBL] [Abstract][Full Text] [Related]
8. A Focused Update on Tardive Dyskinesia.
Blanchet PJ
Can J Neurol Sci; 2020 Nov; 47(6):747-755. PubMed ID: 32624027
[TBL] [Abstract][Full Text] [Related]
9. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.
Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC
Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782
[TBL] [Abstract][Full Text] [Related]
10. The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia.
Liou YJ; Wang YC; Chen JY; Chen ML; Chen TT; Bai YM; Lin CC; Liao DL; Lai IC
Eur J Neurol; 2008 Dec; 15(12):1406-8. PubMed ID: 19049562
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
12. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?
Koola MM; Tsapakis EM; Wright P; Smith S; Kerwin Rip RW; Nugent KL; Aitchison KJ
J Psychopharmacol; 2014 Jul; 28(7):665-70. PubMed ID: 24595968
[TBL] [Abstract][Full Text] [Related]
13. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
Bordia T; Zhang D; Perez XA; Quik M
Exp Neurol; 2016 Dec; 286():32-39. PubMed ID: 27658674
[TBL] [Abstract][Full Text] [Related]
14. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States.
Loughlin AM; Lin N; Abler V; Carroll B
PLoS One; 2019; 14(6):e0216044. PubMed ID: 31163035
[TBL] [Abstract][Full Text] [Related]
15. Association study between the neurexin-1 gene and tardive dyskinesia.
Lanning R; Lett TA; Tiwari AK; Brandl EJ; de Luca V; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Remington G; Kennedy JL; Zai CC
Hum Psychopharmacol; 2017 Jan; 32(1):. PubMed ID: 28120489
[TBL] [Abstract][Full Text] [Related]
16. No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients.
Park YM; Kang SG; Choi JE; Kim YK; Kim SH; Park JY; Kim L; Lee HJ
Psychiatry Investig; 2011 Mar; 8(1):49-54. PubMed ID: 21519536
[TBL] [Abstract][Full Text] [Related]
17. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia.
Loonen AJ; Wilffert B; Ivanova SA
Pharmacogenomics; 2019 Nov; 20(17):1199-1223. PubMed ID: 31686592
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
Witter DP; Holbert RC; Suryadevara U
Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
[TBL] [Abstract][Full Text] [Related]
19. Tardive dyskinesia: Who gets it and why.
Frei K
Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management.
Widschwendter CG; Hofer A
Curr Opin Psychiatry; 2019 May; 32(3):179-184. PubMed ID: 30720484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
